Skip to content
Sign in

PTGX · NASDAQ

Protagonist Therapeutics (PTGX) Stock Price & Fundamentals

$417.74+0.82%+$3.38End-of-day price as of Oct 9, 2026

Protagonist Therapeutics (PTGX) closed at $417.74 on Oct 9, 2026, up 0.82% from the previous close of $414.36.

Share price, past year

1Y +3.01%

52-week range $383.43 – $454.50. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$417.74
Sep 30, 2026$416.86
Aug 31, 2026$425.71
Jul 31, 2026$433.65
Jun 30, 2026$446.65
May 29, 2026$442.23
Apr 30, 2026$414.44
Mar 31, 2026$413.62
Feb 27, 2026$403.30
Jan 30, 2026$414.37
Dec 31, 2025$410.41
Nov 28, 2025$391.86
Oct 31, 2025$408.17

Key statistics

Market cap
$27.02B
P/E (TTM)
405.6
EPS (TTM)
$1.03
Revenue (TTM)
$281.99M
Net income (TTM)
$82.91M
Shares outstanding
64.7M
Dividend yield
—
52-week range
$383.43 – $454.50

Protagonist Therapeutics's market cap is $27.02B, based on a share price of $417.74 and 64.7M shares outstanding as of Jun 30, 2026.

Financials

Protagonist Therapeutics reported revenue of $46.02M for fiscal 2025, down 89.41% from fiscal 2024.

Protagonist Therapeutics reported a net loss of $130.15M in fiscal 2025.

Annual revenue

FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Protagonist Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$46.02M−89.4%−$130.15M−282.8%−$2.05$56.08M
FY2024ended Dec 31, 2024$434.43M+624.1%$275.19M63.3%$4.23$182.80M
FY2023ended Dec 31, 2023$60.00M+125.7%−$78.96M−131.6%−$1.39−$70.85M
FY2022ended Dec 31, 2022$26.58M−2.8%−$127.39M−479.3%−$2.60−$108.93M
FY2021ended Dec 31, 2021$27.36M−4.4%−$125.55M−458.9%−$2.71−$108.97M
FY2020ended Dec 31, 2020$28.63M+12,293.1%−$66.15M−231.1%−$1.92−$72.96M
FY2019ended Dec 31, 2019$231.00K−99.3%−$77.19M−33,414.3%−$2.98−$42.49M
FY2018ended Dec 31, 2018$30.93M+54.1%−$38.92M−125.9%−$1.74−$50.43M
FY2017ended Dec 31, 2017$20.06M—−$36.96M−184.2%−$2.09$3.21M
Protagonist Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$213.48M$162.85M$2.29
Q1 FY2026ended Mar 31, 2026$56.37M$3.78M$0.05
Q4 FY2025ended Dec 31, 2025$7.44M−$44.38M−$0.69
Q3 FY2025ended Sep 30, 2025$4.71M−$39.34M−$0.62
Q2 FY2025ended Jun 30, 2025$5.55M−$34.77M−$0.55
Q1 FY2025ended Mar 31, 2025$28.32M−$11.66M−$0.19
Q4 FY2024ended Dec 31, 2024$170.64M$131.67M$2.01
Q3 FY2024ended Sep 30, 2024$4.68M−$33.21M−$0.54

Company profile

Name
Protagonist Therapeutics, Inc
Ticker
PTGX
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
7707 Gateway Blvd., Suite 140, Newark, CA 94560-1160
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001377121

Recent SEC filings

Frequently asked questions

What is Protagonist Therapeutics's stock price?

Protagonist Therapeutics (PTGX) closed at $417.74 on Oct 9, 2026, up 0.82% from the previous close of $414.36.

What is Protagonist Therapeutics's market cap?

Protagonist Therapeutics's market cap is $27.02B, based on a share price of $417.74 and 64.7M shares outstanding as of Jun 30, 2026.

How much revenue does Protagonist Therapeutics make?

Protagonist Therapeutics reported revenue of $46.02M for fiscal 2025, down 89.41% from fiscal 2024.

What is PTGX's P/E ratio?

Protagonist Therapeutics's price-to-earnings ratio is 405.6, based on trailing twelve-month diluted EPS of $1.03.

Does Protagonist Therapeutics pay a dividend?

Protagonist Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Protagonist Therapeutics, Inc's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures